Momentis Surgical Limited

Momentis Surgical Limited

Early Stage Capital

Register Interest


The law normally requires people who offer financial products to give information to investors before they invest. This information is designed to help investors make an informed decision.

If you are an accredited investor under the definition of that term in Rule 501(a) of Regulation D of the US Securities Act of 1933, the usual rules do not apply to offers of financial products made to you. As a result, you may not receive a complete and balanced set of information.

You will also have fewer other legal protections for these investments. Ask questions, read all documents carefully, and seek independent financial advice before committing yourself.

Transaction Size
USD 40,000,000.00
Share Price
USD 2.90
Minimum Investment
USD 50,000.00
Issue Type
Early Stage Capital
Health Care

The opportunity exists for wholesale investors to express interest in Momentis Surgical Limited. This is another med-tech opportunity coming out of our US based private equity partners who have also introduced our investors to the likes of Airbnb, Orchestra Biomed, Palinter and SpaceX.

Momentis Surgical has set out to transform robotic-assisted surgery, with proprietary technology that has the potential to far surpass today’s best solutions. Providing unprecedented access and maneuverability, the new Momentis Surgical’s Anovo™ Surgical System features miniature, humanoid-shaped robotic arms with human dexterity, superhuman flexibility, and 360˚ articulation. In addition to these features, the system will be sold at a significantly lower price compared to other marketed robotic surgery systems potentially allowing more medical facilities including hospitals and ambulatory surgical centers to access and adopt surgical robotics.

Beyond the current applications for transvaginal procedures, Momentis Surgical is further developing this technology to explore its use in abdominal single and multi-port surgery, as well as other transluminal indications.

Investment Highlights

  • First FDA-authorized (de Novo) miniaturized humanoid robotic platform that mimics a surgeon’s arms
  • Large TAM of $10B+ with a clear product roadmap starting with gynecology
  • Ability to become standard of care
    • Transvaginal approach enables more procedures to be performed, with safer and better outcomes in accordance with societal guideline recommendations 
  • Potential for significant benefits to all stakeholders – patients, physicians, providers and payors
  • Commercial-stage, with attractive revenue growth and long-term gross margin profile outlook implying attractive entry valuation 
  • Meaningful near-term and longer-term growth drivers  
  • Leadership and Board with deep experience and knowledge in surgical robotics

For more information, please refer to the Investor presentation in the documents tab. To be put in contact with the issuer click Register Interest

Momentis Surgical Investor Presentation
August 19, 2022

Join our Business/Issuer newsletter

Our quarterly Issuer newsletter is for businesses and issuers, and contains platform updates and business insights.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.